Identification of novel tumour-associated antigens in canine mammary gland tumour
Article first published online: 20 MAR 2013
© 2013 Blackwell Publishing Ltd
Veterinary and Comparative Oncology
Volume 13, Issue 3, pages 194–202, September 2015
How to Cite
Furuya, M., Funasaki, M., Tani, H. and Sasai, K. (2015), Identification of novel tumour-associated antigens in canine mammary gland tumour. Veterinary and Comparative Oncology, 13: 194–202. doi: 10.1111/vco.12034
- Issue published online: 21 AUG 2015
- Article first published online: 20 MAR 2013
- Manuscript Accepted: 31 JAN 2013
- Manuscript Revised: 27 DEC 2012
- Manuscript Received: 5 NOV 2012
- mammary gland tumour;
- tumour-associated antigen
Canine mammary gland tumour (MGT) is the most common neoplasm in female dogs and has similar biological characteristics to human MGT. Spontaneous canine MGT is a more attractive clinical model in oncological research than that of the murine experimental model. Tumour-associated antigens (TAAs), which are produced in tumour cells, are applied as tumour markers, tumour vaccine antigens and molecular targets of therapeutic drugs. In this study, we have primarily identified 13 different TAAs of canine MGT by serological immunoscreening of cDNA expression library. The results of serological mini-arrays of identified antigens showed that CCDC41 antigen specially reacted with 35% of sera from MGT-dogs and did not react with control sera. We also found that HSPH1 mRNA expression levels increased significantly in MGT tissues. These findings will contribute to the development of diagnostic technologies and translational target therapies for dogs.
Clinical relevance: HSPH1, which is strongly expressed in the tumour tissue, will be a possible vaccine antigen of canine MGT.